NR1H4 and metabolic dysfunction-associated steatotic liver disease: This is the first proof-of-concept phase II trial assessing the safety and efficacy of the non-steroidal FXR agonist PX-104 in patients with NAFLD demonstrating a significant decrease of GGT and ALT levels together with an improvement of insulin sensitivity.